Concomitant use of known potent cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir
Anti-HIV agents: delavirdine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, lopinavir
The participant requires concomitant treatment with the following inhibitors of CYPA:\r\n* Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin\r\n* Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole, posaconazole\r\n* Antidepressants: nefazodone\r\n* Antidiuretic: conivaptan\r\n* Gastrointestinal (GI): cimetidine, aprepitant\r\n* Hepatitis C: boceprevir, telaprevir\r\n* Miscellaneous: Seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids); use of any of anti-retrovirals (delavirdine) or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) is permitted; specifically, ritonavir and cobicistat is permitted for participants considered for the CYPA-inhibitor based ART regimen arm (Stratum A) of the trial; as part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product
Currently taking a strong CYPA inhibitors that cannot be discontinued prior to trial enrollment and for the duration of trial. This includes but is not is limited to: boceprevir clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir.
Current use or anticipated inability to avoid use of drugs that are known strong CYPA/ inhibitors (atazanavir, boceprevir, conivaptan, clarithromycin, grapefruit or grapefruit juice, indinavir, itraconazole, ketoconazole, nelfinavir, nefazodone, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole)
Concomitant medications, any of the following should be considered for exclusion: strong CYPA inhibitors: (Patients must discontinue drug  days prior to starting ruxolitinib), including but not limited to boceprevir, clarithromycin, conivaptam, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazole; in addition, patients will be instructed to avoid grapefruit or grapefruit juice, starfruit, or Seville oranges
Concurrent use of any medications or substances; these include steroids as they may interfere with PF- (OX Ab); also strong CYPA/ inhibitors should be avoided (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole)
Patients receiving any medications or substances that are inhibitors or inducers of CYPA are ineligible; the subject requires concomitant treatment with the following inhibitors of CYPA:\r\n* Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin; specifically, clarithryomycin is permitted for patients considered for this trial\r\n* Antifungals: itraconzaole, ketoconazole, voriconazole, fluconazole, posaconazole\r\n* Antidepressants: nefazodone\r\n* Antidiuretic: conivaptan\r\n* Antiretrovirals: delaviridine or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) or cobicistat-boosted antiretrovirals\r\n* Gastrointestinal (GI): cimetidine, aprepitant\r\n* Hepatitis C: boceprevir, telaprevir\r\n* Miscellaneous: Seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids)
Patients must stop taking ritonavir, idinavir, saquinavir, telithromycin, clarithromycin and nelfinavir  week prior to registration; Note: topical ketoconazole is permitted
Concomitant use of a strong CYPA inhibitors (e.g., itraconazole, telithromycin, clarithromycin, ketoconazole, voriconazole, nefazodone, posaconazole, ritonavir, lopinavir/ritonavir, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) and moderate CYPA inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole. Fosamprenavir, imatinib, verapamil)
Current use or anticipated inability to avoid use of drugs that are known strong cytochrome P family  subfamily A member / (CYPA/) inhibitors (atazanavir, boceprevir, conivaptan, clarithromycin, grapefruit or grapefruit juice, indinavir, itraconazole, ketoconazole, nelfinavir, nefazodone, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole)
The use of strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors, including: itraconazole, clarithromycin, erythromycin, diltiazem, verapamil, delavirdine, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice (or grapefruits)\r\n* Note: If a patient is on a strong CYPA inhibitor, they can be reconsidered for enrollment if they can safely stop said medication; a two week or  half-lives, whichever is longer, washout will be required prior to enrolling on study; subject may not resume medication while receiving apalutamide
Concomitant use of known CYPA inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir
Treatment with p-glycoprotein inhibitors such as cyclosporine A, elacridar, ketoconazole, ritonavir, saquinavir.
Current use or anticipated need for treatment with drugs or foods that are known strong CYPA/ inhibitors including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice; the topical use of these medications (if applicable), such as % ketoconazole cream, is allowed
Patients chronically receiving drugs that are known strong cytochrome P, family , subfamily A, polypeptide / (CYPA/) inhibitors within  days prior to study enrollment, including but not limited to ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit, and grapefruit juice are not eligible
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (indinavir, nelfinavir, atazanavir, ritonavir, clarithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem); use of the aforementioned strong or moderate inhibitors is prohibited <  days prior to registration
Patient cannot be taking strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors such as:\r\n* Antibiotics: clarithromycin, telithromycin, troleandomycin\r\n* Human immunodeficiency virus (HIV) antiviral protease inhibitors: ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir\r\n* Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole\r\n* Antidepressants: nefazodone
Avoid the use of strong CYPA/PgP inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole).
Patients receiving potent cytochrome P, family , subfamily A, polypeptide  (CYPA) (such as but not limited to boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) inhibitors will be excluded from the study
The patient requires treatment with a medication that is a strong inhibitor of CYPA (boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazole).
Patients currently receiving treatment with strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors and treatment that cannot be either discontinued or switched to a different medication prior to starting study drug; patients receiving any medications or substances that are strong inhibitors of CYPA; all azoles but fluconazole are discouraged to be used in patients requiring treatment with antifungal antibiotics; use of the following strong inhibitors is prohibited =<  days prior to registration\r\n* Strong inhibitors of CYPA/; > -fold increase in the plasma area under the curve (AUC) values or more than % decrease in clearance\r\n** Boceprevir (Victrelis)\r\n** Clarithromycin (Biaxin, Biaxin XL)\r\n** Conivaptan (Vaprisol)\r\n** Indinavir (Crixivan)\r\n** Itraconazole (Sporanox)\r\n** Ketoconazole (Nizoral)\r\n** Lopinavir/Ritonavir (Kaletra)\r\n** Mibefradil\r\n** Nefazodone (Serzone)\r\n** Nelfinavir (Viracept)\r\n** Posaconazole (Noxafil)\r\n** Ritonavir (Novir, Kaletra)\r\n** Saquinivir (Fortovase, Invirase)\r\n** Telaprevir (Incivek)\r\n** Telithromycin (Ketek)\r\n** Voriconazole (Vfend)\r\n** Troleandomycin\r\n** Cobicistat\r\n** Tipranavir
Patients cannot receive cytochrome P A (CYPA) inhibiting drugs including antibiotics (clarithromycin, erythromycin, troleandomycin), anti-HIV agents (delavirdine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, lopinavir), antifungals (itraconazole, ketoconazole, fluconazole at doses >  mg/day, voriconazole), antidepressants (nefazodone, fluvoxamine), calcium channel blockers (verapamil, diltiazem) or amiodarone
Patients currently receiving treatment with strong CYPA inhibitors and treatment that cannot be either discontinued or switched to a different medication prior to starting study drug; patients receiving any medications or substances that are strong or moderate inhibitors of CYPA\r\n* Use of the following strong or moderate inhibitors is prohibited =<  days prior to registration; concurrent use is not allowed simultaneously with nilotinib during the study\r\n** Strong inhibitors of CYPA/ > -fold increase in the plasma area under the curve (AUC) values or more than % decrease in clearance\r\n*** Boceprevir (Victrelis)\r\n*** Clarithromycin (Biaxin, Biaxin XL)\r\n*** Conivaptan (Vaprisol)\r\n*** Grapefruit juice\r\n*** Indinavir (Crixivan)\r\n*** Itraconazole (Sporanox)\r\n*** Ketoconazole (Nizoral)\r\n*** Lopinavir/ritonavir (Kaletra)\r\n*** Mibefradil\r\n*** Nefazodone (Serzone)\r\n*** Nelfinavir (Viracept)\r\n*** Posaconazole (Noxafil)\r\n*** Ritonavir (Novir, Kaletra)\r\n*** Saquinivir (Fortovase, Invirase)\r\n*** Telaprevir (Incivek)\r\n*** Telithromycin (Ketek)\r\n*** Voriconazole (Vfend)\r\n** Moderate inhibitors of CYPA/ > -fold in the plasma AUC values or -% decrease in clearance\r\n*** Amprenavir (Agenerase)\r\n*** Aprepitant (Emend)\r\n*** Atazanavir (Reyataz)\r\n*** Ciprofloxacin (Cipro)\r\n*** Darunavir (Prezista)\r\n*** Diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor XR, Diltia XT, Taztia XT, Tiazac)\r\n*** Erythromycin (Erythrocin, E.E.S. , Ery-Tab, Eryc, EryPed, PCE)\r\n*** Fluconazole (Diflucan)\r\n*** Fosamprenavir (Lexiva)\r\n*** Imatinib (Gleevec)\r\n*** Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM)
Patient must not be receiving any medication that is a strong cytochrome P A (CYPA) inhibitor beginning  days prior to first dose of study drug; strong CYPA inhibitors include (but are not limited to): antibiotics such as clarithromycin, telithromycin, troleandomycin; protease inhibitors such as ritonavir, indinavir, saquinavir, nelfinavir, lopinavir; antifungals such as itraconazole, ketoconazole, voriconazole; and antidepressants such as nefazodone
Receiving any medications or substances that are strong or moderate inhibitors of CYPA; use of the following strong or moderate inhibitors are prohibited =<  days prior to randomization:\r\n* Strong inhibitors of CYPA: indinavir (Crixivan), nelfinavir (Viracept), atazanavir (Reyataz), ritonavir (Norvir), clarithromycin (Biaxin, Biaxin XL), itraconazole (Sporanox), ketoconazole (Nizoral), nefazodone (Serzone), saquinavir (Fortovase, Invirase), telithromycin (Ketek)\r\n* Moderate inhibitors of CYPA: aprepitant (Emend), erythromycin (Erythrocin, E.E.S, Ery-Tab, Eryc, EryPed, PCE, fluconazole (Diflucan), grapefruit juice, verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM), diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor XR, Diltia XT, Taztia XT, Tiazac)
Treatment with strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors: \r\n* Cardiovascular: verapamil and diltiazem; \r\n* Antibiotics: clarithromycin, telithromycin, troleandomycin, erythromycin; \r\n* Human Immunodeficiency Virus (HIV): protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir); \r\n* Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole; \r\n* Antidepressants: nefazodone
EXPANSION COHORT ONLY: Treatment with strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors: \r\n* Cardiovascular: verapamil and diltiazem; \r\n* Antibiotics: clarithromycin, telithromycin, troleandomycin, erythromycin; \r\n* Human Immunodeficiency Virus (HIV): protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir); \r\n* Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole; \r\n* Antidepressants: nefazodone
Use of any strong CYPA inhibitor such as ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir, or saquinavir (see Table  )  days before the first dose of study drug or during the study
Chronic concomitant use of strong CYPA inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole).
Concurrent use with strong inhibitors of CYPA (e.g. clarithromycin, grapefruit juice, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, and voriconazole)
Concurrent use with strong inhibitors of CYPA (e.g. clarithromycin, grapefruit juice, itraconazole, ketoconazole, nefazadone, posaconazole, telithromycin, and voriconazole)
The participant requires concomitant treatment with the following inhibitors of CYPA:\r\n* Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin\r\n* Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole, posaconazole\r\n* Antidepressants: nefazodone\r\n* Antidiuretic: conivaptan\r\n* Gastrointestinal (GI): cimetidine, aprepitant\r\n* Hepatitis C: boceprevir, telaprevir\r\n* Miscellaneous: Seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids); use of any of anti-retrovirals (delavirdine) or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) is permitted; specifically, ritonavir and cobicistat is permitted for participants considered for the CYPA-inhibitor based ART regimen arm (Stratum A) of the trial
Patients taking cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors such as ketoconazole, ritonavir, itraconazole, erythromycin, clarithromycin, nelfinavir, fluconazole, amiodarone, cyclosporine, diltiazem, nefazodone, fluvoxamine, verapamil, chloramphenicol, indinavir or saquinavir within  days of treatment
Use of the following strong inhibitors are prohibited =<  days prior to registration\r\n* Boceprevir (Victrelis)\r\n* Clarithromycin (Biaxin, Biaxin XL)\r\n* Conivaptan (Vaprisol)\r\n* Grapefruit juice\r\n* Indinavir (Crixivan)\r\n* Itraconazole (Sporanox)\r\n* Ketoconazole (Nizoral)\r\n* Lopinavir/ritonavir (Kaletra)\r\n* Mibefradil\r\n* Nefazodone (Serzone)\r\n* Nelfinavir (Viracept)\r\n* Posaconazole (Noxafil)\r\n* Ritonavir (Norvir)\r\n* Saquinavir (Invirase)\r\n* Telaprevir (Incivek)\r\n* Telithromycin (Ketek)
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P family , subfamily A, polypeptide  (CYPA); use of the following strong or moderate inhibitors are prohibited =<  days prior to registration\r\n* Strong inhibitors of CYPA:\r\n** > -fold increase in the plasma area under the curve (AUC) values or more than % decrease in clearance\r\n** Indinavir (Crixivan)\r\n** Nelfinavir (Viracept)\r\n** Atazanavir (Reyataz)\r\n** Ritonavir (Norvir)\r\n** Clarithromycin (Biaxin, Biaxin XL)\r\n** Itraconazole (Sporanox)\r\n** Ketoconazole (Nizoral)\r\n** Nefazodone (Serzone)\r\n** Saquinavir (Fortovase, Invirase)\r\n** Telithromycin (Ketek)\r\n* Moderate Inhibitors of CYPA\r\n** > -fold increase in the plasma AUC values or -% decrease in clearance\r\n** Aprepitant (Emend)\r\n** Erythromycin (Erythrocin, E.E.S., Ery-Tab, Eryc, EryPed, PCE)\r\n** Fluconazole (Diflucan)\r\n** Grapefruit juice\r\n** Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM)\r\n** Diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor XR, Diltia XT, Taztia XT, Tiazac)
Use of any of the following medications within the past  months: clarithromycin, telithromycin, chloramphenicol, itraconazole, nefazodone, cobicistat
On scheduled strong or moderate CYPA inhibitors (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole; amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil) within one week of study enrollment
Patients on drugs with strong CYP A inhibitors within the previous two weeks (ketoconazole, clarithromycin, itraconazole, nefazodone, telithromycin)
The subject requires concomitant treatment with the following inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA):\r\n* Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin\r\n* Antifungals: itraconzaole, ketoconazole, voriconazole, fluconazole, posaconazole\r\n* Antidepressants: nefazodone\r\n* Antidiuretic: conivaptan\r\n* Anti-retrovirals: delaviridine or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) or cobicistat-boosted antiretrovirals\r\n* Gastrointestinal (GI): cimetidine, aprepitant\r\n* Hepatitis C: boceprevir, telaprevir\r\n* Miscellaneous: Seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids
Use of potent CYPA inhibitors, including but not limited to ketoconazole, atazanavir, clarithromycin, indinavir,\r\nitraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice
Use of potent CYPA inhibitors, such as ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice
Current use of the following cytochrome P, family , subfamily A, polypeptide  (CYP A) inhibitors are not allowed: boceprevir, clarithromycin, cyclosporine (oral), darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, gemfibrozil, grapefruit juice >  liter per day, itraconazole, lopinavir plus ritonavir, nelfinavir, saquinavir plus ritonavir, telaprevir, tipranavir plus ritonavir
Use of drugs or foods that are known strong CYPA inhibitors, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice.
strong CYPA inhibitors (including, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit, grapefruit juice)